Mark C Willingham
Overview
Explore the profile of Mark C Willingham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
3527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee W, Kim W, Fozzatti L, Park S, Zhao L, Willingham M, et al.
Endocr Relat Cancer
. 2020 Jan;
27(4):209-220.
PMID: 31977311
Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy without effective therapeutic options to improve survival. Steroid receptor coactivator-3 (SRC-3) is a transcriptional coactivator whose amplification and/or overexpression has been identified...
2.
Zhu X, Holmsen E, Park S, Willingham M, Qi J, Cheng S
Oncotarget
. 2018 Nov;
9(83):35408-35421.
PMID: 30459933
Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited options for treatment. Targeting epigenetic modifications via interfering with the interaction between the bromodomain and extra-terminal domain (BET) proteins and...
3.
Park S, Willingham M, Qi J, Cheng S
Endocr Relat Cancer
. 2018 Jun;
25(10):865-877.
PMID: 29914872
Compelling epidemiological evidence shows a strong positive correlation of obesity with thyroid cancer. studies have provided molecular evidence that high-fat-diet-induced obesity promotes thyroid cancer progression by aberrantly activating leptin-JAK2-STAT3 signaling...
4.
Park J, Zhao L, Willingham M, Cheng S
Am J Cancer Res
. 2017 Apr;
7(3):727-739.
PMID: 28401024
Compelling epidemiologic evidence indicates that obesity is a risk factor for human cancers, including breast. However, molecular mechanisms by which obesity could contribute to the development of breast cancer remain...
5.
Enomoto K, Zhu X, Park S, Zhao L, Zhu Y, Willingham M, et al.
J Clin Endocrinol Metab
. 2017 Apr;
102(7):2268-2280.
PMID: 28368473
Context: Recent studies showed that transcription of the MYC gene is driven by the interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. JQ1, a potent...
6.
Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Zhu X, Enomoto K, Zhao L, Zhu Y, Willingham M, Meltzer P, et al.
Clin Cancer Res
. 2016 Jul;
23(2):430-440.
PMID: 27440272
Purpose: New therapeutic approaches are needed for patients with thyroid cancer refractory to radioiodine treatment. An inhibitor of bromodomain and extraterminal domain (BET) proteins, JQ1, shows potent antitumor effects in...
7.
Zhu X, Kim D, Zhao L, Willingham M, Cheng S
Endocr Relat Cancer
. 2016 Jun;
23(7):521-33.
PMID: 27267120
Thyroid cancer is on the rise. Novel approaches are needed to improve the outcome of patients with recurrent and advanced metastatic thyroid cancers. FDA approval of suberoylanilide hydroxamic acid (SAHA;...
8.
Park J, Zhao L, Willingham M, Cheng S
Mol Carcinog
. 2016 Jun;
56(2):489-498.
PMID: 27254276
We have recently identified that phosphorylation at tyrosine (Y)406 is critical for the tumor suppressor functions of the thyroid hormone receptor β1 (TRβ) in a breast cancer line. However, still...
9.
Park J, Han C, Zhao L, Willingham M, Cheng S
Endocr Relat Cancer
. 2015 Nov;
23(1):53-63.
PMID: 26552408
Compelling epidemiologic studies indicate that obesity is a risk factor for many human cancers, including thyroid cancer. In recent decades, the incidence of thyroid cancer has dramatically increased along with...
10.
Gmeiner W, Willingham M, Bourland J, Hatcher H, Smith T, DAgostino Jr R, et al.
J Clin Oncol Res
. 2015 May;
2(4).
PMID: 26020060
Chemotherapy remains of limited use for the treatment of prostate cancer with only one drug, docetaxel, demonstrating a modest survival advantage for treatment of late-stage disease. Data from the NCI...